Background:Salidroside, a phenolic glycoside derived from Rhodiola species, has attracted attention due to its antioxidant, anti-inflammatory, neuroprotective, cardioprotective, and metabolic regulatory activities. However, its clinical translation is limited by low natural abundance, slow plant regeneration, insufficient production scalability, unclear active species, and incomplete exposure–response relationships.Purpose: This review summarizes recent advances in salidroside biosynthesis, pharmacokinetics, pharmacological mechanisms, safety, and clinical translation. We aim to identify key barriers and provide a framework for advancing salidroside toward clinical application.Methods: A systematic literature search was conducted in PubMed, Web of Science, Scopus, Embase, ScienceDirect, Google Scholar, CNKI, and Wanfang databases. Studies on salidroside production, ADME properties, pharmacological mechanisms, toxicology, and clinical evidence were analyzed and synthesized.Results: Advances in synthetic biology, metabolic engineering, and microbial cell factories have improved scalable salidroside production. Its biosynthesis involves tyrosine-derived tyrosol formation followed by UDP-glycosyltransferase (UGT)-mediated glycosylation, with precursor flux, UGT activity, UDP-glucose supply, and redox regulation as major determinants. Pharmacokinetic studies demonstrate rapid absorption, extensive phase II metabolism, and renal elimination, but variability in bioavailability and uncertainty regarding active metabolites remain major challenges. Salidroside exerts broad pharmacological effects through regulation of oxidative stress, inflammation, apoptosis, and stress-response pathways, including Nrf2/HO-1, NF-κB/MAPK, and PI3K/Akt/mTOR signaling. However, most mechanisms remain associative due to limited exposure validation and causal studies. Current safety evidence is generally favorable, although long-term toxicity, drug interactions, and compound-specific clinical data remain insufficient.Conclusion: Salidroside represents a promising biosynthetic and pharmacological candidate, but successful translation requires standardized production, metabolite-informed pharmacokinetic evaluation, integrated PK–PD studies, rigorous safety assessment, and well-designed clinical trials to establish its therapeutic potential.